Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Oct 05, 2012 5:32pm
233 Views
Post# 20454782

RE: Ready for Breakout?

RE: Ready for Breakout?

TheDave2006:

[S] Sometimes it takes a couple of weeks before boards can review proposals being presented to them. Case in point today, Broker 80 appears to have more firepower than brokers 79 & 1.

Lets see how the positioning ahead of the (November's) PEA work out.

Positions for C:BRD from 20121005 to 20121005

House Bought $Val Ave Sold $Val Ave Net $Net
80 National Bank 315,700 319,833 1.013 5,000 5,050 1.01 310,700 -314,783
73 Cormark 43,431 43,449 1.00 0 43,431 -43,449
62 Haywood 45,000 45,000 1.00 4,000 4,000 1.00 41,000 -41,000
111 Fraser Mackenzie 40,000 39,700 0.993 0 40,000 -39,700
99 Jitney 61,000 60,600 0.993 44,500 44,475 0.999 16,500 -16,125
15 UBS 2,500 2,505 1.002 0 2,500 -2,505
83 Mackie 2,542 2,544 1.001 1,731 1,742 1.006 811 -802
57 Interactive 700 701 1.001 700 700 1.00 0 -1
13 Instinet 0 200 196 0.98 -200 196
81 HSBC 0 500 505 1.01 -500 505
89 Raymond James 0 2,000 2,020 1.01 -2,000 2,020
102 Lakeshore 0 3,000 3,030 1.01 -3,000 3,030
39 Merrill Lynch 0 5,500 5,495 0.999 -5,500 5,495
101 Newedge 0 6,500 6,465 0.995 -6,500 6,465
7 TD Sec 19,000 18,840 0.992 27,292 27,358 1.002 -8,292 8,518
19 Desjardins 900 909 1.01 10,000 10,000 1.00 -9,100 9,091
90 Barclays 0 12,300 12,365 1.005 -12,300 12,365
2 RBC 3,000 2,970 0.99 30,700 31,005 1.01 -27,700 28,035
33 Canaccord 0 45,500 44,795 0.985 -45,500 44,795
85 Scotia 0 78,700 79,230 1.007 -78,700 79,230
79 CIBC 33,000 32,790 0.994 154,150 155,715 1.01 -121,150 122,925
1 Anonymous 60,500 60,260 0.996 195,000 195,955 1.005 -134,500 135,695
TOTAL 627,273 630,101 1.005 627,273 630,101 1.005 0 0

Cheers

Stanley

Bullboard Posts